In the Spotlight...
Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma
Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node
Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia
Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias
Previous Digests
Prime time: secondary prolonged DC priming boosts high-affinity T cell responses
April 23, 2025
After initial priming through interaction with dendritic cells (DCs), CD8+ T cells disengage and migrate, but little is known about how cytokine signals are transmitted or received by these cells for differentiation during this migration. Jobin, Seetharama, et al...
Unraveling the role of soluble CTLA-4
April 16, 2025
CTLA-4 is a well established immune checkpoint with a key a role in limiting autoimmunity, but it exists in both membrane-bound (mCTLA-4) and soluble (sCTLA-4) forms, and the different sources, kinetics, and functions of sCTLA-4 in particular are not...
KEYSTONE SYMPOSIA: Cancer Immunotherapy: Clinical Lessons to New Modalities
April 9, 2025
The ACIR team attended the Keystone Symposia on Cancer Immunotherapy: Clinical Lessons to New Modalities held on March 16-19, 2025 in Banff, AB, Canada. This week’s extensive special feature covers select talks from the conference. We have organized the...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
Current Sponsors
